share_log

iBio Inc | SC 13G: Statement of acquisition of beneficial ownership by individuals-ADAR1 Partners, LP(9.27%),ADAR1 Capital Management, LLC(9.27%), etc.

iBio Inc | SC 13G: Statement of acquisition of beneficial ownership by individuals

iBio Inc | SC 13G：超过5%持股股东披露文件
SEC announcement ·  04/05 17:14
Moomoo AI 已提取核心信息
On April 5, 2024, a Schedule 13G filing was made with the United States Securities and Exchange Commission (SEC) indicating that ADAR1 Partners, LP, along with related entities and Daniel Schneeberger, collectively reported a 9.27% ownership stake in iBio Inc. The shares in question amount to 789,293 shares of common stock. ADAR1 Partners, LP is directly holding the shares, while ADAR1 Capital Management, LLC and ADAR1 Capital Management GP, LLC, both managed by Daniel Schneeberger, may be deemed to indirectly beneficially own the securities. The filing, which is based on the number of shares outstanding as reported on April 1, 2024, does not imply any intention to change or influence the control of iBio Inc. The principal business office for the reporting persons is located in Austin, Texas, and the filing was made in accordance with Rule 13d-1(b) of the Securities Exchange Act of 1934.
On April 5, 2024, a Schedule 13G filing was made with the United States Securities and Exchange Commission (SEC) indicating that ADAR1 Partners, LP, along with related entities and Daniel Schneeberger, collectively reported a 9.27% ownership stake in iBio Inc. The shares in question amount to 789,293 shares of common stock. ADAR1 Partners, LP is directly holding the shares, while ADAR1 Capital Management, LLC and ADAR1 Capital Management GP, LLC, both managed by Daniel Schneeberger, may be deemed to indirectly beneficially own the securities. The filing, which is based on the number of shares outstanding as reported on April 1, 2024, does not imply any intention to change or influence the control of iBio Inc. The principal business office for the reporting persons is located in Austin, Texas, and the filing was made in accordance with Rule 13d-1(b) of the Securities Exchange Act of 1934.
2024年4月5日，向美国证券交易委员会（SEC）提交了附表13G文件，表明ADAR1 Partners、LP以及关联实体和丹尼尔·施内伯格共同报告了iBio Inc.9.27％的所有权。有关股票共计789,293股普通股。ADAR1 Partners, LP直接持有股份，而由丹尼尔·施内伯格管理的 ADAR1 资本管理有限责任公司和 ADAR1 资本管理GP, LLC可能被视为间接实益拥有这些证券。该文件基于2024年4月1日报告的已发行股票数量，并不意味着有任何改变或影响iBio Inc.控制权的意图。申报人的主要业务办公室位于德克萨斯州的奥斯汀，该申报是根据1934年《证券交易法》第13d-1（b）条提交的。
2024年4月5日，向美国证券交易委员会（SEC）提交了附表13G文件，表明ADAR1 Partners、LP以及关联实体和丹尼尔·施内伯格共同报告了iBio Inc.9.27％的所有权。有关股票共计789,293股普通股。ADAR1 Partners, LP直接持有股份，而由丹尼尔·施内伯格管理的 ADAR1 资本管理有限责任公司和 ADAR1 资本管理GP, LLC可能被视为间接实益拥有这些证券。该文件基于2024年4月1日报告的已发行股票数量，并不意味着有任何改变或影响iBio Inc.控制权的意图。申报人的主要业务办公室位于德克萨斯州的奥斯汀，该申报是根据1934年《证券交易法》第13d-1（b）条提交的。
有用
没用

该公告为独立文件：

独立文件1  查看翻译

声明：本内容仅用作提供资讯及教育之目的，不构成对任何特定投资或投资策略的推荐或认可。 更多信息